Down 25% in a month, is this ASX 300 company about to sue the UK Government?

What's going on at this healthcare share?

| More on:
Stressed, unhappy and tired scientist with a headache working on a computer in a lab. Worried, anxious and frustrated pathologist, researcher and doctor struggling with burnout, tension and strain.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has taken another tumble on Tuesday.

In afternoon trade, the ASX 300 healthcare share is down almost 4% to $15.55.

This latest decline means its shares are now down over 25% since this time last month.

Why is this ASX 300 share price under pressure?

Investors have been hitting the sell button since the release of its FY 2023 results at the end of August.

For the 12 months ended 30 June, the ASX 300 share delivered a double-digit increase in both revenue and profit. However, as strong as this looked on paper, it was a little short of the market's expectations.

This was partly down to a subdued over-the-counter launch revenue from its first Photo Cosmetic product, Cyacelle.

Also potentially weighing on the Clinuvel share price has been developments in the United Kingdom.

The company noted the following:

During the year, the English National Institute for Health and Care and Excellence (NICE) decided not to recommend SCENESSE for use on the English National Health Service, despite NICE being twice found by its own Appeal Panel to have breached the Equality Act and having acted unfairly in its review of the drug. This decision has resulted in an ongoing asymmetry of access for EPP patients in the UK, with Scottish patients continuing to receive SCENESSE treatment under a patient access scheme.

What's the latest in the UK?

This morning, the ASX 300 share released a letter to shareholders. While its focus was not purely on the UK issue, it did touch on the subject.

Management revealed that it is preparing to potentially take the UK government to court. It explains:

With admitted inability, unwillingness, and in breach of its own guidelines and the UK Equality Act (2010), NICE and NHS England are now unlawfully depriving EPP patients from accessing SCENESSE treatment. In having reserved our rights, we are now preparing a legal dossier refuting NICE's position: this case deserves adjudication calling to attention the inaptitude of NICE-NHS.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »